The GLP-1 Boom Created a Tissue Gap Fillers Were Not Built For

1 hour ago 3

Article content

Cautionary Notes

Article content

Cautionary Note Regarding Preclinical and Regulatory Status. Conexeu Sciences Inc. is a preclinical-stage company. Its product candidates, including the CXU platform and the B.R.E.A.S.T. Bioregenerative Matrix Platform, are investigational, have not been cleared or approved by the U.S. Food and Drug Administration or any other regulatory authority, and have not been demonstrated to be safe or effective for any indication. Preclinical results, including work conducted with third-party research institutions, are not necessarily predictive of results in humans. A targeted 510(k) submission date is not a submission, and a submission is not a clearance. The availability and acceptability of any regulatory predicate is determined by the FDA, and a predicate-based strategy does not guarantee clearance, timing, or reduced review. References to addressable markets describe total category size and do not represent any forecast of the Company’s revenue or market share. Additional information is available in the Company’s filings with the U.S. Securities and Exchange Commission at www.sec.gov.

Article content

Cautionary Note Regarding Forward-Looking Statements. This publication may contain forward-looking statements, including statements regarding Conexeu Sciences Inc.’s development plans, regulatory strategy and anticipated 510(k) submission timing, manufacturing scale-up, preclinical programs, planned expansion into wound care, periodontal, aesthetic, reconstructive, veterinary, and biofabrication markets, anticipated catalysts, and business prospects. Forward-looking statements are not guarantees of future performance and involve known and unknown risks and uncertainties, including scientific, developmental, clinical, manufacturing, regulatory, reimbursement, competitive, financing, intellectual property, and market risks. Statements made in an interview or fireside chat reflect the speaker’s views at the time and are not a substitute for the Company’s official disclosures. Actual results may differ materially from those projected.

Article content

Cautionary Note Regarding Referenced Companies. References to Establishment Labs Holdings Inc., Eli Lilly and Company, AbbVie Inc., and Solventum Corporation are provided solely as market and sector context. Those companies are not peers, competitors, or financial comparables of Conexeu Sciences Inc., and differ substantially in size, stage, capitalization, revenue, regulatory status, operations, and business model. Their results and share performance describe those companies only, are not indicative of Conexeu Sciences Inc.’s prospects or results, and must not be relied upon in evaluating the profiled company. No partnership, affiliation, or endorsement is implied. Miles Harrison serves on the board of directors of Castle Biosciences, Inc., which is referenced solely as biographical background and is not presented as a comparable, partner, or affiliate of Conexeu Sciences Inc.

Article content

Trademarks

Article content

CXU™ and B.R.E.A.S.T.™ are trademarks of Conexeu Sciences Inc. Motiva® is a registered trademark of Establishment Labs Holdings Inc. Mounjaro® and Zepbound® are registered trademarks of Eli Lilly and Company. BOTOX® and Juvederm® are registered trademarks of Allergan, an AbbVie company. Dysport®, Sculptra®, Restylane®, Cetaphil®, Differin®, Proactiv®, and Epiduo® are registered trademarks of their respective owners. All other trademarks referenced are the property of their respective owners. Use of these marks does not imply any affiliation with, sponsorship by, or endorsement from their owners.

Article content

Sources

Article content

1. IPO Edge, “Next GLP-1 Billion-Dollar Market: Fireside Chat with Conexeu Sciences CEO Miles Harrison,” August 3, 2026. Additional coverage: https://finance.yahoo.com/healthcare/articles/next-glp-1-billion-dollar-145554150.html Available at: https://ipo-edge.com/

Article content

2. Conexeu Sciences Inc. news releases dated May 21, May 27, June 3, June 8, June 15, and June 25, 2026, and Company investor materials. Available at: https://ir.conexeu.com/

Article content

3. Establishment Labs Holdings Inc., Eli Lilly and Company, AbbVie Inc., and Solventum Corporation public disclosure and market data, accessed August 7, 2026.

Article content

USA News Group | [email protected]

Article content